U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drive home the urgent need to pass robust drug pricing reforms.”
“The average net price for brand-name prescription drugs in Medicare Part D doubled in the last decade—far faster than inflation,” Wyden said. “It’s time to give Medicare the tools to fight back against high prices.”
U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
